Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis

University of Alabama at Birmingham0 个研究点目标入组 9 人开始时间: 1995年6月1日最近更新: 2011年3月30日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: University of Alabama at Birmingham
入组人数: 9

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

OBJECTIVES:

Evaluate the efficacy and safety of lipid-mediated transfer of the cystic fibrosis transmembrane conductance regulator gene to nasal epithelium in patients with cystic fibrosis.

详细描述

PROTOCOL OUTLINE: Cystic fibrosis transmembrane conductance regulator (CFTR) gene complexed with lipid is administered intranasally to the right inferior turbinate. Lipid without CFTR is administered to the left nostril as a control.

Cohorts of 3 patients are given successively lower doses of CFTR, each dose complexed with 500 micrograms of lipid.

Patients are followed at days 2-12, 15, and 21, then every 3-4 days for 3 weeks, every 2-3 weeks for 10 weeks, and every 3 months thereafter.

研究设计

研究类型: Interventional
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•PROTOCOL ENTRY CRITERIA:
•-Disease Characteristics-- Cystic fibrosis (CF), i.e.: Sweat chloride greater than 60 mEq/L Clinical manifestations of CF Homozygous delta F508 mutation preferred Compound heterozygotes for F508 mutation with pancreatic insufficiency eligible FEV1 greater than 40% of predicted PO2 at least 60 mm Hg on room air No acute or recurrent sinusitis No obstructive nasal polyposis No pneumothorax or hemoptysis, e.g., more than 250 mL blood within 24-hour period, within past year No unstable lung disease with worsening pulmonary symptoms, arterial blood gas, or pulmonary function tests within 2 weeks prior to entry No pulmonary exacerbation within 4 weeks prior to entry --Prior/Concurrent Therapy-- At least 2 months since participation in any other clinical study At least 2 months since DNase At least 4 months since corticosteroids --Patient Characteristics-- Cardiac: No severe cardiac disease Other: No other severe organ system disease, e.g., juvenile-type diabetes mellitus No pregnant women

排除标准

未提供

研究者

发起方

University of Alabama at Birmingham

申办方类型

Other

相似试验

已完成

1 期

Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene TransferCystic Fibrosis

NCT00004471University of Alabama at Birmingham9

终止

2 期

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With BronchiectasisBronchiectasis

NCT04396366Novartis Pharmaceuticals42

已完成

3 期

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic InsufficiencyExocrine Pancreatic InsufficiencyCystic Fibrosis

NCT00449878Anthera Pharmaceuticals163

已完成

1 期

Safety Study in Subjects With Leber Congenital AmaurosisLeber Congenital Amaurosis

NCT00516477Spark Therapeutics, Inc.12

终止

2 期

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease

NCT04268823Novartis Pharmaceuticals54